To assess the potential effect of different PD-L1 expression level, we calculated median OS in patients with high (≥50%) PD-L1 expression level, and observed a similar trend of longer OS in patients with KRAS G12C-positive cancer treated with CIT alone (median, 32.6 months; 95% CI, 19.4-NR) vs patients with KRAS WT cancer (median, 10.0 months; 95% CI, 5.2–17.5; aHR, 0.57; 95% CI, 0.28–1.14, p = 0.11) (Table 2). The gene discussed is KRAS; the disease is cancer.